Morningstar Downgrades Sequoia Fund On Day Michael Pearson Gets Congressional SubpoenaMark Melin
Sequoia Fund, which is known to highly value management teams when evaluating stock picks for its long-only mutual fund, lost big on Valeant Pharmaceuticals, a company with some of the most significant management problems in recent memory. Sequoia Fund had a management shake-up of its own recently. This management reshuffling, and its concentrated bet on the management team at Valeant Pharmaceuticals, have led to a downgrade by investment . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.